Regulatory Flexibility Staring Contest: Will Industry Or FDA Blink First?
Executive Summary
FDA may be able to talk in theoretical terms about the flexibility it is afforded for orphan products approvals, but others seem to want more tangible evidence. For its part, the agency wants more than general complaints about its regulations; it wants an open discussion of specific roadblocks.
You may also be interested in...
US FDA Should Offer Formal Declaration Of Orphan Drug Flexibility, Attorney Says
Attorney Frank Sasinowski says the agency should include new "boilerplate language" in official documents describing scientific flexibility for orphan drug approval requirements.
Accelerated Approval Should Be Less 'Wide Open,' Califf Says
FDA should write more about its interpretation of regs and apply it more consistently across divisions, commissioner says.
Rare Disease Integration Into FDA Reviews Will Grow Under PDUFA VI
Stakeholders wonder about impact of placing orphan drug program staff "into review teams" as part of next iteration of user fee program.